mTOR inhibitors have been increasingly used for the treatment of PEComas in recent years, either as a first-line treatment in inoperable malignant cases or as adjuvant therapy after surgery [51]. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.